Acelyrin Goes From Float To Sink

A catastrophic late-stage clinical failure wipes 60% off the group’s value – and boosts a rival. 

Illustration of human skin cells.
• Source: Shutterstock

Acelyrin, Inc. was a rare success story in this year’s moribund biotech IPO market, raising $540m on the NASDAQ in May in the third-largest biotech flotation since 2018. Investors who piled in at the IPO price of $18 initially did nicely; the shares closed 11 September at $27.90. 

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D